Glycated hemoglobin (HbA1c) has been used in clinical practice for more than 20 years in the monitoring of diabetes mellitus (DM). Since 2010, it has also been recommended as a diagnostic test for DM in the general population, with a cut-off point of 6.5% [12] . The use of HbA1c to diagnose DM in patients with chronic kidney disease is not currently recommended due to some physiological and analytical factors that could possibly affect HbA1c results, such as uremia, hemodialysis and erythropoietin use [13] . Few studies have evaluated the accuracy of HbA1c for PTDM in renal transplantation, and the results until now have been controversial [9] . It is supposed that a lower cut-off point would be ideal to reduce the number of false-negative (FN) PTDM cases. In this way, the HbA1c cut-off point of 6.2% has also been investigated and discussed [9, 10, 14] .
HbA1c is measured in whole blood samples as well as immunosuppressive drug levels, and there is no requirement for fasting. PTDM development needs to be strictly monitored after transplantation and several glucose blood tests may be required in the first year, which makes HbA1c more attractive and comfortable than the OGTT [7] .
In this study, we conducted a systematic review and metaanalysis to determine the overall diagnostic accuracy of HbA1c for the diagnosis of PTDM in renal transplant recipients.
M A T E R I A L S A N D M E T H O D S

Search strategy
We conducted this meta-analysis according to the guidelines of Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA; Supplementary Material 1) [15] . An electronic search was conducted using PubMed (MEDLINE), Embase and SCOPUS databases through to June 2016. Study keywords were: (i) text or subheading words registered in PubMed or Embase related to DM, HbA1c and renal transplantation; and (ii) text words related to PTDM. Details of search terms are shown in Supplementary Material 2. Gray literature was also searched on Google Scholar. From the papers retrieved, a manual search of their references was conducted. The revision of titles was followed by a reading of the abstracts that could be relevant for the review. Finally, the identification of eligible studies was made, based on a full reading of the articles selected.
Selection criteria
Inclusion criteria were: (i) full articles or abstracts using original data; (ii) cross-sectional or cohort study that assessed the use of HbA1c for the diagnosis of PTDM; (iii) glucose levels measured in all subjects by both OGTT (reference test) and HbA1c (index test); (iv) HbA1c method standardized/certified by the National Glycohemoglobin Standardisation Programme (http://www.ngsp.org/, 6 December 2016, date last accessed) and/or International Federation of Clinical Chemistry [16] ; (v) articles with data necessary for drawing 2Â2 tables; and (vi) studies that included renal transplant recipients without DM prior to transplantation or PTDM already diagnosed.
All possible qualified studies were considered for review, regardless of the language. We excluded studies that diagnosed PTDM based only on fasting plasma glucose (FPG) values as well as review articles and comments. Two reviewers (A.L.P. and G.C.) independently evaluated the title, abstract and subsequently, the full text, and performed data extraction of all studies included in this review. Any disagreements were resolved by a third reviewer (J.L.C.).
Data collection and analysis
The following data were extracted: (i) first author's name; (ii) publication year; (iii) country of origin; (iv) sample size; (v) study design; (vi) age; (vii) HbA1c mean value; (viii) PTDM incidence; (ix) time after transplant; (x) HbA1c method; (xi) truepositive (TP) cases; (xii) false-positive (FP) cases; (xiii) truenegative (TN) cases; and (xiv) FN cases. When necessary, additional information on 2Â2 tables was obtained by requesting them directly from the authors. When data were not available from the authors, the study was excluded.
Assessing methodological quality
The quality of primary studies was assessed independently by two researches (A.L.P. and G.C.) using the Quality Assessment for Studies of Diagnostic Accuracy QUADAS-2 checklist, which is a validated tool to evaluate the risk of bias and concerns regarding applicability in studies of diagnostic accuracy. It consists of four key domains that evaluate patient selection, index test, reference standard and flow of patients, and timing of the index test and reference standard [17] . Disagreements were resolved by review or discussion with a third researcher (J.L.C.).
Statistical analysis and data synthesis
We used the standard methods recommended for diagnostic accuracy meta-analyses studies [18] . TP, TN, FP and FN rates were obtained to construct a 2Â2 contingency table.
The following indexes of HbA1c test accuracy were computed for each study by a bivariate model using a random effects approach [19] : sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR) and diagnostic odds ratio (DOR). PLR >1 for a positive test result is associated with the presence of disease, and NLR <1 for a negative test result is associated with the absence of disease [20] . The DOR is a single indicator that summarizes the diagnostic accuracy of a test, and higher values indicate a better test performance [21] . Hierarchical summary receiver operating characteristics curves (HSROC) were used to summarize the overall HbA1c performance [22] . The Fagan nomogram was applied, considering a pre-test probability of 20% [3, 23] . The heterogeneity among studies was evaluated by the inconsistency test (I   2   ) , where 0%, 25%, 50% and 75% indicate, respectively, absent, low, moderate and high heterogeneity [24] . The presence of publication bias was tested by using Deeks' funnel plots [25] . A P-value <0.05 was considered statistically significant in all analyses except for Deeks' test, where a value of P < 0.1 was considered statistically significant. 
The forest plots were constructed using Review Manager version 5.3 (Cochrane Collaboration, Oxford, UK). Our analyses were based on previously published studies; therefore, no ethical approval was required.
R E S U L T S
Study selection and characteristics
The initial search strategy identified 694 studies, 11 of which were assessed for eligibility. Three studies were excluded for duplicate data [26] [27] [28] , one did not meet the research question [11] and one had insufficient data to draw the 2Â2 table [29] . Finally, six studies met the eligibility criteria and were included in the systematic review and meta-analysis ( Figure 1 ) [10, 14, [30] [31] [32] [33] .
In this study, we were able to perform three sub-metaanalyses according to the HbA1c cut-off point and the time after transplantation. HbA1c of 6.5% was evaluated separately in the initial months after transplant and at the end of the first year, and HbA1c of 6.2% was only evaluated in the initial months after transplant. Table 1 summarizes the characteristics of selected studies. Three had prospective design [14, 31, 32] , two were cross-sectional studies [10, 30] and one presented a prospective cross-sectional analysis [33] , all published between 2013 and 2016.
Study quality
The quality assessment of the studies is described in Supplementary Table S1 . All studies presented a low risk of bias and applicability concerns. Two studies presented an unclear risk of bias in the patient selection [30, 32] . One study [30] described that 300 patients underwent an OGTT, but the HbA1c results were available for only 120 of them; therefore, we cannot affirm that there was no risk of bias in the patient selection. Since it was a letter, some information was not described. Furthermore, although it presented the clinical and laboratory characteristics of 120 patients, only 119 were classified according to OGTT; it was not clear why one patient was excluded from the analysis. Lastly, we had to retrieve data on HbA1c methodology from the institutional laboratory information. In the other study [32] , the total number of patients who underwent kidney transplant in the institution during the study period was not clear, nor were the causes of their exclusion from the study.
Meta-analysis
HbA1c !6.5% to diagnose PTDM in the initial months after renal transplantation. All six studies included in this review evaluated HbA1c !6.5% to diagnose PTDM in the initial months after renal transplant (10 weeks up to 4 months), totaling 2057 individuals [10, 14, [30] [31] [32] [33] .
Forest plots of sensitivity and specificity of the six studies are shown in Figure 2A and the summary of diagnostic accuracy of HbA1c !6.5% early after transplant is presented in Table 2 . The DOR was 22.13 [95% confidence interval (95% CI) 10.05-48.72; I 2 ¼ 54.6%, P ¼ 0.051]. After re-running the meta-analysis by removing one paper at a time, no paper explained the moderate DOR heterogeneity, and no study was excluded from the primary meta-analysis. The area under the curve (AUC) was 0.96 (95% CI 0.94-0.97; Figure 3A) .
When the pre-test probability of 20% was combined with the PLR and NLR, the post-test probabilities for PTDM were 75% P o s t -t r a n s p l a n t a t i o n d i a b e t e s m e l l i t u s a n d H b A 1 c Figure S1a) showed a statistically non-significant value (P ¼ 0.41), indicating that there was no potential publication bias.
HbA1c !6.5% to diagnose PTDM at 12 months after renal transplantation. Two studies evaluated HbA1c !6.5% to diagnose PTDM at the end of the first year after renal transplantation, totaling 112 individuals [14, 33] .
The metandi command in Stata software requires a minimum of four studies to compute data [34] . For this reason, the random effect model in Meta-DiSc was used to summarize estimates in this sub-meta-analysis [35] . Forest plots of sensitivity and specificity of the two studies are shown in Figure 2B .
Pooling these studies together, we found a sensitivity of 0. HbA1c !6.2% to diagnose PTDM in the initial months after renal transplantation. We performed a sub-metaanalysis of four studies to evaluate the diagnostic accuracy of HbA1c !6.2% to diagnose PTDM early after transplantation (10 weeks up to 4 months), totaling 1888 individuals [10, 14, 31, 32] . Forest plots of sensitivity and specificity are shown in Figure 2C , and the summary of diagnostic accuracy of HbA1c !6.2% for PTDM is presented in Table 2 . The DOR was 26.29 (95% CI 8.91-77.55; I 2 ¼ 32%, P ¼ 0.220). After rerunning the meta-analysis by removing the study by Eide et al. [31] , the heterogeneity was 0.0%. A similar result was found after removing the study by Shabir et al. [14] . After a careful evaluation, we were not able to explain the reasons why they individually contributed to the increase in heterogeneity for HbA1c !6.2% and they were not excluded from the primary meta-analysis. The AUC was 0.91 (95% CI 0.88-0.93; Figure 3B) .
After combining the pre-test probability of 20% with the PLR and NLR, the post-test probabilities for PTDM were 64% for HbA1c !6.2% and 6% for HbA1c <6.2% ( Figure 4B) .
The Deeks' test (Supplementary Figure S1b) showed a statistically non-significant value (P ¼ 0.1), indicating that there was no potential publication bias.
D I S C U S S I O N
In this systematic review with meta-analyses, we determined the overall diagnostic accuracy of HbA1c for the diagnosis of PTDM in renal transplant recipients in the initial months after transplant and at the end of the first year. Six studies met the eligibility criteria to be included, all presenting a low risk of bias and applicability concerns. P o s t -t r a n s p l a n t a t i o n d i a b e t e s m e l l i t u s a n d H b A 1 c
| | | | | | | |
An HbA1c value of 6.5% in the early period after transplant showed a low sensitivity to confirm the presence of PTDM. As well as for DM in the general population [36] , this point showed high specificity, and an HbA1c result !6.5% is unlikely to be an FP for PTDM, increasing the post-test probability for the disease almost 4-fold [9] . The AUC and DOR values confirm the high accuracy and good HbA1c test performance to discriminate individuals with and without PTDM. The sub-meta-analysis evaluating four studies for HbA1c of 6.2% in the early period after transplant showed that this point also presented a high level of accuracy for PTDM with the posttest probability three times higher. Lowering 0.3% in HbA1c cut-off point during the early period after transplant, from 6.5% to 6.2%, increased the sensitivity in almost 30% and decreased specificity in 10%. This reduction might be interesting if we consider the higher number of TP cases of PTDM that would be diagnosed. The decrease from 96% to 89% in the specificity seems not to represent a great concern at this point in time since these patients are constantly monitored after transplantation.
The results of HbA1c diagnostic accuracy in our metaanalysis of renal transplant recipients showed similar results to studies conducted in the general population, where HbA1c presents high specificity and low-to-moderate sensitivities compared with glycemic tests [36] [37] [38] [39] . A large cross-sectional study that included older adults from the Rancho Bernardo Study evaluated the use of HbA1c !6.5% compared with OGTT as well as diabetic retinopathy for diabetes diagnosis. The authors found values of 44% and 79% for sensitivity and specificity, respectively, and an AUC of 0.65, which is a worse performance than in transplant recipients [39] . The use of lower HbA1c cutpoints such as 6.0%, 6.1% and 6.2%, which showed better performance in the general population, has been suggested as an attempt to increase the sensitivity without causing drastic changes in the specificity [38, 40] . It is known that some factors such as dialysis treatment, uremia, the use of recombinant erythropoietin and anemia may be found in the recent period after transplantation and interfere with HbA1c results [13, 41] . Not all studies included in this review reported the exclusion of patients with these conditions. However, taking into consideration the results of our meta-analyses and those presented in the literature for the general population, these factors seem not to affect HbA1c performance after renal transplantation as it has presented good accuracy for PTDM.
Only two studies with small sample sizes were included in the sub-meta-analysis that evaluated the HbA1c point of 6.5% at the end of the first year after transplant, which makes them difficult to interpret. Although summary estimates of sensitivity and specificity have shown similar results to those of the initials months after transplantation, they have presented wide confidence intervals. Studies with larger sample sizes are required to better evaluate the diagnostic accuracy of HbA1c at the end of the first year after renal transplantation.
A study conducted in renal transplant patients at 10 weeks after transplantation assessed the accuracy of fasting plasma glucose and HbA1c for the selection of patients who should undergo an OGTT, and that was the first time the HbA1c test was included in an algorithm for PTDM [11] . Since then, other studies have suggested different algorithms to increase sensitivity for PTDM diagnosis, including HbA1c alone or in combination with fasting glucose. The use of HbA1c !6.2% to rule in and HbA1c 5.8% to rule out PTDM reduced the number of OGTT by 85% at 4 months after transplant [10] , and HbA1c !6.2% combined with FPG !126 mg/dL failed to detect 16% of kidney recipients with PTDM at 10 weeks after transplantation [31] .
As for the strengths of this study, the study was conducted through an extensive and systematic literature search, the overall quality of original studies was checked and most studies presented low risk of bias and applicability concerns. Still, we evaluated the use of HbA1c in a specific group of patients from different institutions with similar clinical conditions in the post-transplant period. The maintenance of immunosuppression was similar in all institutions and comprised the use of corticosteroid, calcineurin inhibitor and mycophenolate [10, 14, [30] [31] [32] [33] .
This review also presents some limitations. First, although we only included studies that measured HbA1c with standardized methods, the individual performance of each laboratory was not available. Second, the period in which HbA1c was measured in the early period after transplant ranged from 10 weeks to 4 months. PTDM consensus recommends that PTDM diagnosis be done after a patient achieves steady doses of immunosuppressive drugs, which is unlikely before 3 months after transplant, to minimize blood glucose variations and avoid misdiagnosis [9] . Despite this, excluding the study by Eide et al. [31] from the sub-meta-analysis of HbA1c of 6.5% did not reduce the DOR heterogeneity. Although it is known that in the early period after transplant the glucose levels are higher [9] , the incidence of PTDM in this study was the lowest of all included studies. The large biological variation of OGTT is a limitation for its use as a reference test in this study [42] . Furthermore, glucose values may vary within the same patient from one day to another as a consequence of changes in immunosuppressive drug levels. However, pending the results of studies on the relation of OGTT, HbA1c and FPG early post-transplantation and future development of microvascular complications, our study adequately reflects the available knowledge.
In conclusion, we conducted the first systematic review with meta-analysis concerning HbA1c diagnostic accuracy for PTDM. According to our results, HbA1c of 6.5% and HbA1c of 6.2% presented high specificity to confirm the presence of PTDM between 10 weeks and 4 months after transplant, but the low/moderate sensitivity limits its isolated use as a screening test.
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